. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2016 Mar 8;22(6):1094–1101. doi: 10.1016/j.bbmt.2016.02.017

TABLE 3.

Association between select exposures with early and later onset cardiomyopathy risk among ≥1-year HCT survivors.

Exposure	Before 1-year OR (95% CI)^*	After 1-year HR (95% CI)^†
Anthracycline, mg/m²
None	1.0 (ref)	1.0 (ref)
<250	1.4 (0.5–3.6)	*2.4 (1.2–4.9)*
≥250	*4.0 (1.7–9.1)*	*2.6 (1.3–5.2)*

Chest radiotherapy
Pre-transplant	1.3 (0.5–3.5)	0.9 (0.3–2.3)
Total body irradiation (TBI)	-	1.3 (0.7–2.6)

Autologous donor	-	*2.5 (1.1–5.8)*

History of chronic GVHD	-	1.3 (0.6–2.8)

History of post-transplant relapse	-	1.7 (0.8–3.6)

Pre-transplant cardiovascular conditions
Hypertension	*4.2 (1.8–9.8)*	1.8 (0.7–4.6)
Dyslipidemia	2.2 (0.7–7.1)	1.1 (0.3–4.0)
Diabetes	0.3 (0.05–1.3)	1.7 (0.5–5.7)

≥1-year post-transplant cardiovascular conditions
Hypertension	-	*2.1 (1.1–4.1)*
Dyslipidemia	-	1.6 (0.8–3.3)
Diabetes	-	*2.9 (1.3–6.5)*

HR, hazard ratio; OR, odds ratio

Logistic regression model adjusted for sex, age at and year of HCT, anthracycline dose, pre-transplant chest radiotherapy (not TBI).

^†

Cox proportional hazards models adjusted for same covariates as logistic regression models, plus TBI, donor status, history of chronic GVHD, and history of post-transplant relapse.